$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

$egrx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000082787123000009 Filed on March 23, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$66.31M	$60.70M	$316.6M
YoY Change	-42.78%	43.43%	84.56%
Cost Of Revenue	$17.30M	$19.87M	$94.94M
YoY Change	-31.28%	61.39%	201.12%
Gross Profit	$49.01M	$40.83M	$221.7M
YoY Change	-45.97%	36.06%	58.32%
Gross Profit Margin	73.91%	67.27%	70.01%
Selling, General & Admin	$27.96M	$24.15M	$106.6M
YoY Change	26.05%	18.82%	41.56%
% of Gross Profit	57.06%	59.14%	48.1%
Research & Development	$9.272M	$7.217M	$34.09M
YoY Change	51.8%	90.57%	-33.52%
% of Gross Profit	18.92%	17.67%	15.38%
Depreciation & Amortization	$100.0K	$5.630M	$646.0K
YoY Change	-50.0%	427.65%	-15.45%
% of Gross Profit	0.2%	13.79%	0.29%
Operating Expenses	$37.23M	$31.37M	$140.7M
YoY Change	31.61%	30.09%	11.15%
Operating Profit	$11.77M	$9.466M	$80.96M
YoY Change	-80.32%	60.47%	2823.8%
Interest Expense	$1.516M	-$1.663M	-$3.774M
YoY Change	314.21%	-63.29%	-330.83%
% of Operating Profit	12.88%	-17.57%	-4.66%
Other Income/Expense, Net	-$1.542M	$5.501M	-$15.75M
YoY Change	-28.91%	-3893.79%	115.29%
Pretax Income	$10.23M	$13.30M	$61.43M
YoY Change	-82.26%	986.93%	-1450.77%
Income Tax	$4.481M	$5.139M	$25.79M
% Of Pretax Income	43.8%	38.63%	41.98%
Net Earnings	$5.750M	$8.165M	$35.64M
YoY Change	-86.95%	-231.78%	-513.14%
Net Earnings / Revenue	8.67%	13.45%	11.26%
Basic Earnings Per Share	$0.44		$2.76
Diluted Earnings Per Share	$0.44	$0.62	$2.73
COMMON SHARES
Basic Shares Outstanding	13.08M shares	13.02M shares	12.93M shares
Diluted Shares Outstanding	13.15M shares		13.07M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$21.90M	$55.32M	$55.32M
YoY Change	-71.0%	-46.28%	-43.35%
Cash & Equivalents	$21.90M	$55.32M	$55.32M
Short-Term Investments		$0.00
Other Short-Term Assets	$2.575M	$13.20M	$13.20M
YoY Change	-45.93%	317.85%	11.02%
Inventory	$44.14M	$47.79M	$47.79M
Prepaid Expenses
Receivables	$115.0M	$72.44M	$72.44M
Other Receivables	$1.069M	$0.00	$0.00
Total Short-Term Assets	$192.5M	$188.8M	$188.8M
YoY Change	-19.85%	9.36%	9.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.116M	$1.168M	$1.168M
YoY Change	-31.41%	-28.61%	-28.61%
Goodwill	$45.03M	$45.03M
YoY Change	13.31%	13.31%
Intangibles	$112.9M	$118.3M
YoY Change	1035.56%	1008.87%
Long-Term Investments
YoY Change
Other Assets	$33.51M	$52.88M	$52.88M
YoY Change	349.32%	414.48%	81.86%
Total Long-Term Assets	$221.7M	$217.4M	$217.4M
YoY Change	177.11%	167.99%	167.99%
TOTAL ASSETS
Total Short-Term Assets	$192.5M	$188.8M	$188.8M
Total Long-Term Assets	$221.7M	$217.4M	$217.4M
Total Assets	$414.2M	$406.2M	$406.2M
YoY Change	29.36%	60.07%	60.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.11M	$18.99M	$18.99M
YoY Change	17.91%	15.59%	15.59%
Accrued Expenses	$73.20M	$85.84M	$85.84M
YoY Change	15.44%	165.46%	165.46%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$7.500M	$6.250M	$6.250M
YoY Change	-68.35%	-75.59%	-75.59%
Total Short-Term Liabilities	$97.81M	$111.1M	$111.1M
YoY Change	-3.77%	49.36%	49.36%
LONG-TERM LIABILITIES
Long-Term Debt	$68.83M	$56.22M	$56.22M
YoY Change
Other Long-Term Liabilities	$4.692M	$5.297M	$5.297M
YoY Change	83.07%	82.47%	82.47%
Total Long-Term Liabilities	$73.52M	$61.51M	$61.51M
YoY Change	2768.55%	2018.95%	2018.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$97.81M	$111.1M	$111.1M
Total Long-Term Liabilities	$73.52M	$61.51M	$61.51M
Total Liabilities	$171.3M	$172.6M	$172.6M
YoY Change	64.42%	123.35%	123.35%
SHAREHOLDERS EQUITY
Retained Earnings	$117.3M	$111.5M
YoY Change	-2.22%	46.98%
Common Stock	$18.00K	$18.00K
YoY Change	5.88%	5.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$243.1M
YoY Change		8.0%
Treasury Stock Shares		4.553M shares
Shareholders Equity	$242.8M	$233.6M	$233.6M
YoY Change
Total Liabilities & Shareholders Equity	$414.2M	$406.2M	$406.2M
YoY Change	29.36%	60.07%	60.07%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	$5.750M	$8.165M	$35.64M
YoY Change	-86.95%	-231.78%	-513.14%
Depreciation, Depletion And Amortization	$100.0K	$5.630M	$646.0K
YoY Change	-50.0%	427.65%	-15.45%
Cash From Operating Activities	-$33.51M	$37.56M	$50.70M
YoY Change	101.75%	364.76%	79.67%
INVESTING ACTIVITIES
Capital Expenditures	$58.00K	$10.00K	$178.0K
YoY Change	-65.48%	-120.41%	-44.89%
Acquisitions			$74.15M
YoY Change
Other Investing Activities	-$12.50M	$1.000K	-$86.65M
YoY Change			1633.04%
Cash From Investing Activities	-$12.56M	-$9.000K	-$86.83M
YoY Change	7375.0%	-81.63%	1531.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$1.250M		$52.24M
YoY Change	-37.5%		552.95%
Cash From Financing Activities	$12.65M	2.389M	-$6.209M
YoY Change	-211.34%	-123.62%	-78.13%
NET CHANGE
Cash From Operating Activities	-$33.51M	37.56M	$50.70M
Cash From Investing Activities	-$12.56M	-9.000K	-$86.83M
Cash From Financing Activities	$12.65M	2.389M	-$6.209M
Net Change In Cash	-$33.42M	39.94M	-$42.34M
YoY Change	18.79%	-2018.2%	670.34%
FREE CASH FLOW
Cash From Operating Activities	-$33.51M	$37.56M	$50.70M
Capital Expenditures	$58.00K	$10.00K	$178.0K
Free Cash Flow	-$33.57M	$37.55M	$50.52M
YoY Change	100.07%	361.83%	81.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0000827871
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-36306
CY2022	dei	Entity Registrant Name EntityRegistrantName	Eagle Pharmaceuticals, Inc.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8179278
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	50 Tice Boulevard
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 315
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Woodcliff Lake
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07677
CY2022	dei	City Area Code CityAreaCode	201
CY2022	dei	Local Phone Number LocalPhoneNumber	326-5300
CY2022	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value per share
CY2022	dei	Trading Symbol TradingSymbol	EGRX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	412548056	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13084243	shares
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Stamford, Connecticut
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	55321000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97659000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	72439000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	41149000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	47794000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	21908000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13200000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11890000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	188754000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	172606000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1168000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1636000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	118327000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	10671000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	45033000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	39743000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	27146000	usd
CY2021Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	18798000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	25732000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10278000	usd
CY2022Q4	us-gaap	Assets Assets	406160000	usd
CY2021Q4	us-gaap	Assets Assets	253732000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18993000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	16431000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	85844000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32338000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	6250000	usd
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	25607000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	111087000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	74376000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5297000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2903000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	56216000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2022Q4	us-gaap	Liabilities Liabilities	172600000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	77279000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17569375	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16903034	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	18000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	17000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	366265000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	325779000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1112000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-94000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	111504000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	75862000	usd
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	4552730	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	4111622	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	243115000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	225111000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	233560000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	176453000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	406160000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	253732000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	316610000	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	171546000	usd
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	187802000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	85458000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	31528000	usd
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	33647000	usd
CY2022	us-gaap	Royalty Expense RoyaltyExpense	9478000	usd
CY2021	us-gaap	Royalty Expense RoyaltyExpense	10652000	usd
CY2020	us-gaap	Royalty Expense RoyaltyExpense	11818000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34088000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51275000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30785000	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	106626000	usd
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	75322000	usd
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	78598000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	168777000	usd
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	154848000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	32954000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-15753000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-19527000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7317000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	61433000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4548000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	22677000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25791000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4079000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10688000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	35642000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-8627000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	11989000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.76
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.89
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.73
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.87
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12933896	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13051095	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13481525	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13065494	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13051095	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13771393	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	35642000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-8627000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	11989000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1112000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	94000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-94000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1018000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-94000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	0	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	34624000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8721000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	11989000	usd
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	179174000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24756000	usd
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3654000	usd
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1525000	usd
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
CY2020	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	32037000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	11989000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	186011000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19555000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2398000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-1577000	usd
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	21213000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-94000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-8627000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	176453000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16451000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1747000	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	23645000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-1356000	usd
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	18004000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1018000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	35642000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	233560000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	35642000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-8627000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	11989000	usd
CY2022	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-8324000	usd
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-3618000	usd
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1511000	usd
CY2022	us-gaap	Depreciation Depreciation	646000	usd
CY2021	us-gaap	Depreciation Depreciation	764000	usd
CY2020	us-gaap	Depreciation Depreciation	872000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1243000	usd
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1046000	usd
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1228000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11378000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2996000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2666000	usd
CY2022	egrx	Debt Securities Available For Sale Credit Loss Expense Reversal DebtSecuritiesAvailableForSaleCreditLossExpenseReversal	0	usd
CY2021	egrx	Debt Securities Available For Sale Credit Loss Expense Reversal DebtSecuritiesAvailableForSaleCreditLossExpenseReversal	758000	usd
CY2020	egrx	Debt Securities Available For Sale Credit Loss Expense Reversal DebtSecuritiesAvailableForSaleCreditLossExpenseReversal	0	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	16451000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	19555000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	24756000	usd
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-4457000	usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-6170000	usd
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-5300000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	469000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	472000	usd
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	419000	usd
CY2022	egrx	Fair Value Adjustment On Accelerated Share Repurchases FairValueAdjustmentOnAcceleratedShareRepurchases	0	usd
CY2021	egrx	Fair Value Adjustment On Accelerated Share Repurchases FairValueAdjustmentOnAcceleratedShareRepurchases	0	usd
CY2020	egrx	Fair Value Adjustment On Accelerated Share Repurchases FairValueAdjustmentOnAcceleratedShareRepurchases	2962000	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-962000	usd
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	686000	usd
CY2020	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
CY2022	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	263000	usd
CY2021	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	usd
CY2020	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	usd
CY2022	egrx	Accretion Income AccretionIncome	0	usd
CY2021	egrx	Accretion Income AccretionIncome	148000	usd
CY2020	egrx	Accretion Income AccretionIncome	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4444000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	30832000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9529000	usd
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3113000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8339000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	13833000	usd
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1509000	usd
CY2022	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	5155000	usd
CY2021	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	2770000	usd
CY2020	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-11386000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2966000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	10162000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	806000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	43580000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	7770000	usd
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4429000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	18624000	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	1321000	usd
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets And Liabilities Net IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet	2325000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	50701000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	28219000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	49497000	usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	74152000	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2022	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	12500000	usd
CY2021	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	0	usd
CY2020	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	17500000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	178000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	323000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	747000	usd
CY2022	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	0	usd
CY2021	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	5000000	usd
CY2020	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-86830000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5323000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18247000	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	18004000	usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	21213000	usd
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	34999000	usd
CY2022	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	30000000	usd
CY2021	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	usd
CY2020	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	110000000	usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	15000000	usd
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	usd
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	110000000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	50000000	usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	52236000	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	8000000	usd
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	5000000	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	1360000	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1356000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1577000	usd
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1525000	usd
CY2022	egrx	Payments For Employee Options Exercised PaymentsForEmployeeOptionsExercised	0	usd
CY2021	egrx	Payments For Employee Options Exercised PaymentsForEmployeeOptionsExercised	0	usd
CY2020	egrx	Payments For Employee Options Exercised PaymentsForEmployeeOptionsExercised	0	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1747000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2398000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3654000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6209000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-28392000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-37870000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-42338000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-5496000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6620000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97659000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	103155000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109775000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	55321000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97659000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	12500000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	28410000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	10005000	usd
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	6428000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1726000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1197000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	270000	usd
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	855000	usd
CY2022	egrx	Number Of Products Launched NumberOfProductsLaunched	6	product
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements including disclosure</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of contingent assets and contingent liabilities at</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. Our critical accounting policies are those that are both most important to our financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. As of the date of issuance of these financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, assumptions and judgments or revise the carrying value of our assets or liabilities. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates, and any such differences may be material to our financial statements. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from sales of products is recognized at the point where the customer obtains control of the goods and we satisfy our performance obligation, which generally is at the time we ship the product to the customer. Provisions for chargebacks, rebates, discounts, and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> returns are established in the same period the related sales are recognized. Significant judgments must be made in determining the transaction price for our sales of products related to anticipated rebates, discounts and returns. Refer below for further details.</span></div>
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	ReclassificationsCertain reclassifications have been made to prior year amounts to conform with the current year presentation in certain notes to these consolidated financial statements.
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	47567000	usd
CY2022Q4	us-gaap	Other Assets Fair Value Disclosure OtherAssetsFairValueDisclosure	8125000	usd
CY2022Q4	us-gaap	Fair Value Liabilities Measured On Recurring Basis Obligations FairValueLiabilitiesMeasuredOnRecurringBasisObligations	4063000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	57357000	usd
CY2021Q4	us-gaap	Receivables Fair Value Disclosure ReceivablesFairValueDisclosure	4021000	usd
CY2021Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Asset EmbeddedDerivativeFairValueOfEmbeddedDerivativeAsset	962000	usd
CY2022	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	8500000	usd
CY2021	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2600000	usd
CY2020	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2700000	usd
CY2022Q4	egrx	Revenue From Contract With Customer Wholesaler Discount RevenueFromContractWithCustomerWholesalerDiscount	0.02
CY2020Q4	egrx	Sales Revenue Allowance SalesRevenueAllowance	11802000	usd
CY2021	egrx	Sales Revenue Allowance Provisions And Adjustments SalesRevenueAllowanceProvisionsAndAdjustments	42893000	usd
CY2021	egrx	Sales Revenue Allowance Credits And Payments SalesRevenueAllowanceCreditsAndPayments	44766000	usd
CY2021Q4	egrx	Sales Revenue Allowance SalesRevenueAllowance	9929000	usd
CY2022	egrx	Sales Revenue Allowance Provisions And Adjustments SalesRevenueAllowanceProvisionsAndAdjustments	187804000	usd
CY2022	egrx	Sales Revenue Allowance Credits And Payments SalesRevenueAllowanceCreditsAndPayments	130831000	usd
CY2022Q4	egrx	Sales Revenue Allowance SalesRevenueAllowance	66902000	usd
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2509450	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2435002	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2974678	shares
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	35642000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	35642000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-8627000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8627000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	11989000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12933896	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13051095	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	13481525	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	131598	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2020	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	289868	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13065494	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13051095	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	13771393	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.76
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.89
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.73
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.87
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	12348000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	7317000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	14064000	usd
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	9666000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	21382000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4925000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	47794000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	21908000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7769000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7591000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6601000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5955000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1168000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1636000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	646000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	764000	usd
CY2022Q4	egrx	Advancestocommercialmanufactures Advancestocommercialmanufactures	5464000	usd
CY2021Q4	egrx	Advancestocommercialmanufactures Advancestocommercialmanufactures	2354000	usd
CY2022Q4	egrx	Prepaid Fda User Fee And Advances To Clinical Research Organizations PrepaidFDAUserFeeAndAdvancesToClinicalResearchOrganizations	3022000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2021Q4	egrx	Prepaid Fda User Fee And Advances To Clinical Research Organizations PrepaidFDAUserFeeAndAdvancesToClinicalResearchOrganizations	1108000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	258000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	196000	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	90000	usd
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	1173000	usd
CY2022Q4	egrx	Prepaid Research And Development PrepaidResearchAndDevelopment	106000	usd
CY2021Q4	egrx	Prepaid Research And Development PrepaidResearchAndDevelopment	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	5312000	usd
CY2022Q4	egrx	Pass Through Receivables PassThroughReceivables	1001000	usd
CY2021Q4	egrx	Pass Through Receivables PassThroughReceivables	347000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3259000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1400000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13200000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11890000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7205000	usd
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	5085000	usd
CY2022Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	1549000	usd
CY2021Q4	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	4100000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5541000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2013000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5293000	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	8466000	usd
CY2022Q4	egrx	Accrued Product Sales Reserves Current AccruedProductSalesReservesCurrent	33000000	usd
CY2021Q4	egrx	Accrued Product Sales Reserves Current AccruedProductSalesReservesCurrent	4390000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1534000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1309000	usd
CY2022Q4	egrx	Inventory Received But Not Invoiced InventoryReceivedButNotInvoiced	6779000	usd
CY2021Q4	egrx	Inventory Received But Not Invoiced InventoryReceivedButNotInvoiced	6177000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	5182000	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	usd
CY2022Q4	us-gaap	Nonfinancial Liabilities Fair Value Disclosure NonfinancialLiabilitiesFairValueDisclosure	4063000	usd
CY2021Q4	us-gaap	Nonfinancial Liabilities Fair Value Disclosure NonfinancialLiabilitiesFairValueDisclosure	0	usd
CY2022Q4	egrx	Royalty Buy Down Payable RoyaltyBuyDownPayable	15000000	usd
CY2021Q4	egrx	Royalty Buy Down Payable RoyaltyBuyDownPayable	0	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	698000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	798000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	85844000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32338000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P2Y
CY2022Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	21213000	usd
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	34999000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1507000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1407000	usd
CY2022	us-gaap	Lease Cost LeaseCost	1507000	usd
CY2021	us-gaap	Lease Cost LeaseCost	1407000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1507000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	1407000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	270000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.060
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1534000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1508000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3042000	usd
CY2022	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	6250000	usd
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1300000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	6250000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	10000000	usd
CY2022Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	47500000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	63750000	usd
CY2022	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	441108	shares
CY2021	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	429446	shares
CY2020	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	774489	shares
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	18004000	usd
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1934193	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3331890	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	59.20
CY2020Q4	egrx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Nonexercisable Number SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingNonexercisableNumber	1028142	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2303748	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	114000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	46.74
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	122847	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	27.64
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	508165	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	62.00
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2814878	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	58.51
CY2021Q4	egrx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Nonexercisable Number SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingNonexercisableNumber	472916	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2341962	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	139700	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	44.15
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	91255	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	25.74
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	437490	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	62.89
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2425833	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	57.51
CY2022Q4	egrx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Outstanding Nonexercisable Number SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingNonexercisableNumber	310622	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	2115211	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	20.49
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	23.62
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	28.98
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4900000	usd
CY2022	egrx	Sharebased Compensation Arrangementby Sharebased Payment Award Options Exercised Intrinsic Value SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExercisedIntrinsicValue	1700000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y2M12D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2500000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	13800000	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11600000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16451000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19555000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24756000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16451000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19555000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24756000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	30933000	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	6912000	usd
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	10140000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3181000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	785000	usd
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2059000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	34114000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7697000	usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	12199000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-7607000	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3030000	usd
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1227000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-740000	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-588000	usd
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-284000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	24000	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-8323000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3618000	usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1511000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25791000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4079000	usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10688000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.03
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.06
CY2022	egrx	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefit	-0.02
CY2021	egrx	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefit	0.44
CY2020	egrx	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefit	-0.04
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.01
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.31
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.02
CY2022	egrx	Effective Income Tax Rate Reconciliation Limitation On Executive Compensation Percent EffectiveIncomeTaxRateReconciliationLimitationOnExecutiveCompensationPercent	0.03
CY2021	egrx	Effective Income Tax Rate Reconciliation Limitation On Executive Compensation Percent EffectiveIncomeTaxRateReconciliationLimitationOnExecutiveCompensationPercent	-0.60
CY2020	egrx	Effective Income Tax Rate Reconciliation Limitation On Executive Compensation Percent EffectiveIncomeTaxRateReconciliationLimitationOnExecutiveCompensationPercent	0.09
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.13
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.40
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.09
CY2022	egrx	Effective Income Tax Rate Transaction Costs EffectiveIncomeTaxRateTransactionCosts	0.03
CY2021	egrx	Effective Income Tax Rate Transaction Costs EffectiveIncomeTaxRateTransactionCosts	0
CY2020	egrx	Effective Income Tax Rate Transaction Costs EffectiveIncomeTaxRateTransactionCosts	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.02
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.04
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.01
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.01
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.42
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.90
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.47
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	46996000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1563000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	9875000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10405000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	4197000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	3190000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	3405000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	2123000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	205000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	1240000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4559000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4207000	usd
CY2022Q4	egrx	Deferred Tax Assets Operating Lease Right Of Use Liability DeferredTaxAssetsOperatingLeaseRightOfUseLiability	688000	usd
CY2021Q4	egrx	Deferred Tax Assets Operating Lease Right Of Use Liability DeferredTaxAssetsOperatingLeaseRightOfUseLiability	962000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	471000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	329000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	7579000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3659000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1489000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	81634000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	25508000	usd
CY2022Q4	egrx	Installment Sale Malta InstallmentSaleMalta	484000	usd
CY2021Q4	egrx	Installment Sale Malta InstallmentSaleMalta	485000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	59000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	45000	usd
CY2022Q4	egrx	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	255000	usd
CY2021Q4	egrx	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	300000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	648000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	921000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	18530000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Inventory Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts	2981000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Inventory Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	247000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	23204000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1751000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35101000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4959000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	23329000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	18798000	usd
CY2022	egrx	Number Of Tax Jurisdictions Currently Auditing The Company NumberOfTaxJurisdictionsCurrentlyAuditingTheCompany	3	jurisdiction
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	5500000	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	30100000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3207000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1672000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1122000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	413000	usd
CY2022Q4	egrx	Lessee Operating Lease Liability To Be Paid After Year Three LesseeOperatingLeaseLiabilityToBePaidAfterYearThree	0	usd
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	12500000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	12500000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	0	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	0	usd
CY2022Q4	egrx	Contractual Obligation To Be Paid After Year Three ContractualObligationToBePaidAfterYearThree	0	usd
CY2022Q4	us-gaap	Purchase Obligation PurchaseObligation	87501000	usd
CY2022Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	87501000	usd
CY2022Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	0	usd
CY2022Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	usd
CY2022Q4	egrx	Purchase Obligation To Be Paid After Year Three PurchaseObligationToBePaidAfterYearThree	0	usd
CY2022Q4	egrx	Obligation Obligation	166958000	usd
CY2022Q4	egrx	Obligation To Be Paid Year One ObligationToBePaidYearOne	107923000	usd
CY2022Q4	egrx	Obligation To Be Paid Year Two ObligationToBePaidYearTwo	11122000	usd
CY2022Q4	egrx	Obligation To Be Paid Year Three ObligationToBePaidYearThree	47913000	usd
CY2022Q4	egrx	Obligation To Be Paid After Year Three ObligationToBePaidAfterYearThree	0	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1507000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1407000	usd
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1323000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3207000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3207000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	165000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3042000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	12500000	usd
CY2022Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	12500000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	134783000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	16456000	usd
CY2022Q4	egrx	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	0	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	118327000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	23850000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13179000	usd
CY2021Q4	egrx	Finite Lived Intangible Assets Impairment FiniteLivedIntangibleAssetsImpairment	0	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10671000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	11400000	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3000000	usd
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2700000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	21916000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	19770000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	13908000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	11606000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	11606000	usd
CY2022Q4	egrx	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	39521000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	118327000	usd

Files In Submission

Name	View Source	Status
0000827871-23-000009-index-headers.html	Edgar Link	pending
0000827871-23-000009-index.html	Edgar Link	pending
0000827871-23-000009.txt	Edgar Link	pending
0000827871-23-000009-xbrl.zip	Edgar Link	pending
egrx-20221231.htm	Edgar Link	pending
egrx-20221231.xsd	Edgar Link	pending
egrx-20221231_g1.jpg	Edgar Link	pending
exhibit21110k2022.htm	Edgar Link	pending
exhibit23110k2022.htm	Edgar Link	pending
egrx-20221231_def.xml	Edgar Link	unprocessable
egrx-20221231_pre.xml	Edgar Link	unprocessable
egrx-20221231_lab.xml	Edgar Link	unprocessable
egrx-20221231_htm.xml	Edgar Link	completed
exhibit31110k2022.htm	Edgar Link	pending
exhibit31210k2022.htm	Edgar Link	pending
exhibit32110k2022.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
egrx-20221231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

2023 Q1 Form 10-K Financial Statement

#000082787123000009 Filed on March 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX EAGLE PHARMACEUTICALS, INC. Stock $egrx

2023 Q1 Form 10-K Financial Statement

#000082787123000009 Filed on March 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx